相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Alopecia areata is associated with risk of inflammatory arthritis
Colin M. Kincaid et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2023)
Comparison of melanoma guidelines in the USA, Canada, Europe, Australia and New Zealand: a critical appraisal and comprehensive review
Z. V. Fong et al.
BRITISH JOURNAL OF DERMATOLOGY (2014)
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Local and Regional Therapies for Melanoma: Many Arrows in the Quiver
John F. Thompson
JOURNAL OF SURGICAL ONCOLOGY (2014)
Isolated Limb Infusion with Melphalan and Actinomycin D for Melanoma: A Systematic Review
Hidde M. Kroon et al.
JOURNAL OF SURGICAL ONCOLOGY (2014)
Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study
Pippa G. Corrie et al.
LANCET ONCOLOGY (2014)
Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study
James Larkin et al.
LANCET ONCOLOGY (2014)
Final Trial Report of Sentinel-Node Biopsy versus Nodal Observation in Melanoma
D. L. Morton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice
Chengwen Liu et al.
CLINICAL CANCER RESEARCH (2013)
PIK3CA overexpression is a possible prognostic factor for favorable survival in ovarian clear cell carcinoma
Azusa Abe et al.
HUMAN PATHOLOGY (2013)
Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor
Kevin B. Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Melanoma Epidemic: An Analysis of Six Decades of Data From the Connecticut Tumor Registry
Alan C. Geller et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2013)
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
Meghna Das Thakur et al.
NATURE (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
Antoni Ribas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Tumor Homogeneity between Primary and Metastatic Sites for BRAF Status in Metastatic Melanoma Determined by Immunohistochemical and Molecular Testing
Lucile Boursault et al.
PLOS ONE (2013)
Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma
Alexander M. Menzies et al.
CLINICAL CANCER RESEARCH (2012)
BRAF Inhibitors for the Treatment of Metastatic Melanoma: Clinical Trials and Mechanisms of Resistance
Alexander Marzuka Alcala et al.
CLINICAL CANCER RESEARCH (2012)
BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Melanoma
Kevin B. Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma
Alexander M. M. Eggermont et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
BRAF/NRAS Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma
Maria Colombino et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild et al.
LANCET (2012)
Variation in number of general practitioner consultations before hospital referral for cancer: findings from the 2010 National Cancer Patient Experience Survey in England
Georgios Lyratzopoulos et al.
LANCET ONCOLOGY (2012)
Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial
Bryan H. Burmeister et al.
LANCET ONCOLOGY (2012)
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
Kim Margolin et al.
LANCET ONCOLOGY (2012)
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
Georgina V. Long et al.
LANCET ONCOLOGY (2012)
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Effect of adding a diagnostic aid to best practice to manage suspicious pigmented lesions in primary care: randomised controlled trial
Fiona M. Walter et al.
BMJ-BRITISH MEDICAL JOURNAL (2012)
Cutaneous melanoma attributable to sunbed use: systematic review and meta-analysis
Mathieu Boniol et al.
BMJ-BRITISH MEDICAL JOURNAL (2012)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032
Maria J. Sambade et al.
RADIOTHERAPY AND ONCOLOGY (2011)
Teledermatology for diagnosis and management of skin conditions: A systematic review
Erin M. Warshaw et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2011)
Revised UK guidelines for the management of cutaneous melanoma 2010
J. R. Marsden et al.
JOURNAL OF PLASTIC RECONSTRUCTIVE AND AESTHETIC SURGERY (2010)
Interferon Alpha Adjuvant Therapy in Patients With High-Risk Melanoma: A Systematic Review and Meta-analysis
Simone Mocellin et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Final Version of 2009 AJCC Melanoma Staging and Classification
Charles M. Balch et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Sentinel-node biopsy or nodal observation in melanoma
Donald L. Morton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Excision margins in high-risk malignant melanoma
JM Thomas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma
MB Lens et al.
BRITISH JOURNAL OF DERMATOLOGY (2004)
Adjuvant interferon in high-risk melanoma: The AIM HIGH study-United Kingdom Coordinating Committee on cancer research randomized study of adjuvant low-dose extended-duration interferon alfa-2a in high-risk resected malignant melanoma
BW Hancock et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
分享论文
